Sareum Collaborates with Almirall Prodesfarma
News Aug 10, 2005
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Almirall Prodesfarma S.A., to provide protein structure determination capabilities to accelerate drug discovery research at Almirall.
Sareum will utilise its skills in high throughput protein expression, purification and structure determination with the aim of illustrating the precise nature of how Almirall's potential drug candidates interact with their target proteins.
This information will assist Almirall's scientists in their design of new and improved therapeutics against inflammatory diseases.
Sareum's Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that Almirall has chosen Sareum as their partner in protein structure determination."
He adds, "This is a further important collaboration that Sareum has signed since we started trading on AIM. We look forward to successful delivery of this project to Almirall and to closing additional partnerships such as this."
Almiralls's General Director for Research & Development, Dr José M Palacios, said: "We consider protein structure determination as an essential element in a modern drug discovery strategy, and we have high expectations that this collaboration with Sareum will allow Almirall to significantly leverage its drug discovery capacity."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.